The Pfizer-BioNTech COVID-19 Vaccine: Remarkably Effective

摘要

In a large placebo-controlled trial, ≥ 7 days after completion of a two-dose regimen, this mRNA vaccine showed 95% efficacy against COVID-19 with relatively mild side effects. The rapid development of SARS-CoV-2 vaccines is one of the few bright spots of 2020. The lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine developed by BioNTech and Pfizer, BNT162b2, is among the most anticipated vaccines. Now, researchers have examined the safety and efficacy of a regimen of two 30-μg doses in a multinational placebo-controlled, industry-sponsored trial.